about
Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risksEfficacy and tolerability of agomelatine in the treatment of depressionComparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.Involvement of adrenoceptors, dopamine receptors and AMPA receptors in antidepressant-like action of 7-O-ethylfangchinoline in mice.N-acetylserotonin: neuroprotection, neurogenesis, and the sleepy brainAgomelatine for Depression in Schizophrenia: A Case-SeriesAgomelatine in the treatment of depressive disorders in clinical practice: multicenter observational CHRONOS studyPharmacotherapy of insomnia.Drugs for insomnia.Role of melatonin in mood disorders and the antidepressant effects of agomelatine.Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder.Agomelatine in treating generalized anxiety disorder.New insights on the antidepressant discontinuation syndrome.Current Phase II investigational therapies for insomnia.Synthetic melatoninergic ligands: achievements and prospects.Fibromyalgia syndrome: novel therapeutic targets.Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement.Effects of depression and melatonergic antidepressant treatment alone and in combination with sedative-hypnotics on heart rate variability: Implications for cardiovascular risk.Agomelatine reduces brain, kidney and liver oxidative stress but increases plasma cytokine production in the rats with chronic mild stress-induced depression.
P2860
Q28651497-25A4AE8A-A5AA-46C2-A15F-AD712254A144Q33583450-0762C797-674D-48DC-87BA-275579747396Q34040072-99055D93-0E7D-410C-8444-7A1B1B846849Q36044838-0C885572-4CCA-4C8D-8541-6AA4763AA967Q36173713-F3470D34-3674-4EB5-A2C1-BCE06F8562BFQ37299879-1D35B211-B1CC-4DAC-AFEA-01B7567B36CFQ37724201-672C4D29-CCB0-43C5-9CCB-4BAE0CB93778Q38009370-79292325-DF48-44E3-BE5E-7B09F93B0269Q38017272-62C332A0-3DFC-4B0E-9ECC-58CC9236A499Q38033191-BB3DC2A7-94B4-4021-9066-F5E8760361FCQ38203356-BEA3C65C-F4FE-442A-ACFE-24397B69B21DQ38207149-1D6142C2-1BAB-45BD-9B06-D765CBCB159FQ38238790-A1422638-D92A-406D-A2D9-8FD9C8465134Q38271292-629C8336-83F5-4F37-910A-9FBA4E98F37DQ38457000-8184A238-E4C4-44EB-9098-3A884AF5CAF8Q38863908-A30FE60A-7175-42D7-B3E2-3E13CFD91BBAQ47604739-5182EE59-3DEE-48EB-A349-14A2404097E9Q47949399-BB83973E-30AF-44B0-8B03-45B87D1175DCQ48048163-4E6AAFE5-2CA2-487A-B2A1-6ADDDCB564D6
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Agomelatine: a narrative review.
@en
Agomelatine: a narrative review.
@nl
type
label
Agomelatine: a narrative review.
@en
Agomelatine: a narrative review.
@nl
prefLabel
Agomelatine: a narrative review.
@en
Agomelatine: a narrative review.
@nl
P1476
Agomelatine: a narrative review.
@en
P2093
Koen Demyttenaere
P304
P356
10.1016/J.EURONEURO.2011.07.004
P407
P478
21 Suppl 4
P577
2011-08-10T00:00:00Z